Clascoterone Keeps Gaining Ground in Acne Two identical Phase 3 trials (plus a long‑term extension) randomized patients ≥12 years with moderate‑to‑severe acne to twice‑daily clascoterone 1% cream or vehicle for…
Small Channels, Smarter Delivery - A Practical Boost For Topical And Regenerative Approaches Microneedling is proving to be a low‑risk, clinic-friendly way to enhance topical therapies (most consistently 5% minoxidil, now…
Dupilumab in Diverse Skin — Are Adverse Events Really the Same? Atopic dermatitis isn’t one-size-fits-all: chronic type 2 inflammation, barrier dysfunction, and S. aureus colonization are core features, but presentation…